» Articles » PMID: 9773763

Psychosocial Factors Influencing the Short-term Outcome of Antithyroid Drug Therapy in Graves' Disease

Overview
Journal Psychosom Med
Specialty Psychiatry
Date 1998 Oct 17
PMID 9773763
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Although psychological stress and smoking have been proposed as factors contributing to Graves' disease, their independent roles in the course of this disease have not been determined. We assessed the association between the course of Graves' disease and psychosocial factors by using multivariate analysis.

Methods: We investigated the association between the short-term outcome of Graves' disease (assessed 12 months after the beginning of antithyroid drug therapy) and stressful life events, daily hassles, smoking, drinking habits, coping skills, and social support (before and 6 months after beginning therapy) in 230 patients (182 women and 48 men) with newly diagnosed Graves' disease, using a logistic regression model.

Results: After adjustment for smoking, coping skills, and thyroid function, daily hassles scores in women at 6 months after beginning therapy were significantly associated with a hyperthyroid state 12 months after beginning therapy. The relative risk was 3.9 for women with higher daily hassles scores compared with women with lower daily hassles scores (95% confidence interval, 1.1 to 13.2; p < .05). Smoking was not significantly associated with a hyperthyroid state 12 months after beginning therapy in either women or men.

Conclusions: Chronic psychological stress is associated with the course of Graves' disease in women.

Citing Articles

What is the impact of stress on the onset and anti-thyroid drug therapy in patients with graves' disease: a systematic review and meta-analysis.

Wang J, Chen Z, Carru C, Capobianco G, Sedda S, Li Z BMC Endocr Disord. 2023; 23(1):194.

PMID: 37700292 PMC: 10496195. DOI: 10.1186/s12902-023-01450-y.


Stress-Related Immune Response and Selenium Status in Autoimmune Thyroid Disease Patients.

Vaivode I, Zake T, Strele I, Upmale-Engela S, Gogins D, Gersone G Int J Mol Sci. 2023; 24(3).

PMID: 36768762 PMC: 9917185. DOI: 10.3390/ijms24032440.


Graves' disease and mental disorders.

Fukao A, Takamatsu J, Arishima T, Tanaka M, Kawai T, Okamoto Y J Clin Transl Endocrinol. 2019; 19:100207.

PMID: 31763175 PMC: 6864135. DOI: 10.1016/j.jcte.2019.100207.


Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence.

Liu J, Fu J, Xu Y, Wang G Int J Endocrinol. 2017; 2017:3813540.

PMID: 28529524 PMC: 5424485. DOI: 10.1155/2017/3813540.


[Endocrine ophthalmopathy. A visible psychophysical complaint].

Strempel I Ophthalmologe. 2016; 113(2):126-30.

PMID: 26801325 DOI: 10.1007/s00347-015-0212-6.